PA Medical News about macular degeneration

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effects of combination therapy with verteporfin photodynamic therapy and ranibizumab in patients with age-related macular degeneration
Acta Ophthalmologica, 11/06/09

Wolf–Schnurrbusch UEK et al. – There were no visual safety concerns and intraocular pressures remained normal. Only two serious adverse events were recorded over the 12–month period, and neither was considered to be related to treatment. Same–day verteporfin plus ranibizumab improved VA, reduced CRT, prevented CNV perfusion and reduced lesion area safely over 12 months.

<< Previous
Autosomal Dominant Polycystic Kidney Disease: New Treatment...

Next >>
Airway Inflammation in Cement Production Workers

Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration
Retina, 11/11/09 Relevance Score: 68%

Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial
Ophthalmology, 10/28/09 Relevance Score: 68%

siRNA therapeutics for age-related macular degeneration: promises and pitfalls
Expert Review of Ophthalmology, 10/22/09 Relevance Score: 68%

Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
American Journal of Ophthalmology, 10/07/09 Relevance Score: 67%

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections
Acta Ophthalmologica, 11/11/09 Relevance Score: 66%